NO20034705L - Aripiprazol oral lösning - Google Patents

Aripiprazol oral lösning

Info

Publication number: NO20034705L
Authority: NO; Norway
Prior art keywords: oral solution; aripiprazole oral; aripiprazole; solution; oral
Prior art date: 2001-04-25

Application number

NO20034705A

Other languages

English (en)

Other versions

NO324606B1 (no

NO20034705D0 (no

Inventor

Prakash Parab

Joyce Chou

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-25

Filing date

2003-10-21

Publication date

2003-11-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23099862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20034705(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-10-21 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2003-10-21 Publication of NO20034705D0 publication Critical patent/NO20034705D0/no

2003-11-28 Publication of NO20034705L publication Critical patent/NO20034705L/no

2007-11-26 Publication of NO324606B1 publication Critical patent/NO324606B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Psychiatry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20034705A 2001-04-25 2003-10-21 Farmasøytisk løsning egnet for oral administrering omfattende aripiprazol. NO324606B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28671801P	2001-04-25	2001-04-25
PCT/US2002/013048 WO2002085366A1 (en)	2001-04-25	2002-04-24	Aripiprazole oral solution

Publications (3)

Publication Number	Publication Date
NO20034705D0 NO20034705D0 (no)	2003-10-21
NO20034705L true NO20034705L (no)	2003-11-28
NO324606B1 NO324606B1 (no)	2007-11-26

Family

ID=23099862

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20034705A NO324606B1 (no)	2001-04-25	2003-10-21	Farmasøytisk løsning egnet for oral administrering omfattende aripiprazol.

Country Status (36)

Country	Link
US (1)	US6977257B2 (no)
EP (2)	EP2436384B2 (no)
JP (1)	JP4401077B2 (no)
KR (1)	KR100909329B1 (no)
CN (1)	CN1512884B (no)
AR (1)	AR033168A1 (no)
AT (1)	ATE537831T1 (no)
AU (1)	AU2002254722B2 (no)
BG (1)	BG66177B1 (no)
BR (1)	BR0208986A (no)
CA (1)	CA2445276C (no)
CY (1)	CY1112606T1 (no)
CZ (1)	CZ306181B6 (no)
DK (1)	DK1381367T3 (no)
EE (1)	EE05581B1 (no)
ES (1)	ES2377855T3 (no)
GE (1)	GEP20053602B (no)
HR (1)	HRP20030870B1 (no)
HU (1)	HU230456B1 (no)
IL (2)	IL158202A0 (no)
IS (1)	IS2863B (no)
MX (1)	MXPA03009728A (no)
MY (1)	MY129350A (no)
NO (1)	NO324606B1 (no)
NZ (1)	NZ528550A (no)
PE (1)	PE20021086A1 (no)
PL (1)	PL206882B1 (no)
PT (1)	PT1381367E (no)
RS (1)	RS52082B (no)
RU (1)	RU2295960C2 (no)
SK (1)	SK287948B6 (no)
TW (1)	TWI337865B (no)
UA (1)	UA76144C2 (no)
UY (1)	UY27273A1 (no)
WO (1)	WO2002085366A1 (no)
ZA (1)	ZA200307797B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6770478B2 (en) *	2000-02-10	2004-08-03	The Regents Of The University Of California	Erythrocytic cells and method for preserving cells
RU2342931C2 (ru) *	2002-08-20	2009-01-10	Бристол-Маерс Сквибб Компани	Состав на основе комплекса арипипразола
EP1680144B1 (en) *	2003-10-08	2011-10-05	Mallinckrodt LLC	Methylphenidate solution and associated methods of administration and production
CA2543242C (en)	2003-10-23	2015-04-14	Otsuka Pharmaceutical Co., Ltd.	Controlled release sterile freeze-dried aripiprazole formulation and injectable formulation thereof
US20080234291A1 (en) *	2004-01-21	2008-09-25	Marc Karel Jozef Francois	Mitratapide Oral Solution
US20070148100A1 (en)	2005-09-15	2007-06-28	Elan Pharma International, Limited	Nanoparticulate aripiprazole formulations
EP1808165B1 (en) *	2006-01-05	2009-04-29	Teva Pharmaceutical Industries Ltd	Dry formulations of aripiprazole
EP1808164B2 (en) *	2006-01-05	2018-07-04	Teva Pharmaceutical Industries Ltd	Wet granulation method for preparing pharmaceutical compositions of aripiprazole
JP4892264B2 (ja) *	2006-03-30	2012-03-07	高田製薬株式会社	リスペリドン水性液剤
ATE523602T1 (de) *	2006-06-12	2011-09-15	Hadasit Med Res Service	Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen
GB0618879D0 (en)	2006-09-26	2006-11-01	Zysis Ltd	Pharmaceutical compositions
MX2010001311A (es) *	2007-07-31	2010-04-21	Otsuka Pharma Co Ltd	Metodo para producir una suspensi?n de aripiprazol y formulacion liofilizada.
WO2009042166A1 (en) *	2007-09-25	2009-04-02	Panacos Pharmaceuticals, Inc.	Liquid bevirimat dosage forms for oral administration
GB2456183A (en) *	2008-01-04	2009-07-08	Gw Pharma Ltd	Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
US8551973B2 (en)	2008-12-23	2013-10-08	Gilead Pharmasset Llc	Nucleoside analogs
SG172359A1 (en)	2008-12-23	2011-07-28	Pharmasset Inc	Nucleoside phosphoramidates
NZ593647A (en)	2008-12-23	2013-08-30	Gilead Pharmasset Llc	Synthesis of purine nucleosides
TWI598358B (zh)	2009-05-20	2017-09-11	基利法瑪席特有限責任公司	核苷磷醯胺
JP5664871B2 (ja) *	2009-06-19	2015-02-04	株式会社メドレックス	アリピプラゾールと有機酸を有効成分とする外用剤組成物
TR201000948A1 (tr)	2010-02-09	2011-08-22	Sanovel İlaç San.Ve Ti̇c.A.Ş.	Aripiprazol formülasyonları.
TW201136945A (en)	2010-03-31	2011-11-01	Pharmasset Inc	Purine nucleoside phosphoramidate
PL3290428T3 (pl)	2010-03-31	2022-02-07	Gilead Pharmasset Llc	Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
JP2013527145A (ja)	2010-03-31	2013-06-27	ギリード・ファーマセット・エルエルシー	リン含有活性化剤の立体選択的合成
PT3042910T (pt)	2010-11-30	2019-04-16	Gilead Pharmasset Llc	2'-espiro-nucleósidos para utilização na terapia da hepatite c
PL2685979T3 (pl)	2011-03-18	2017-02-28	Alkermes Pharma Ireland Limited	Kompozycje farmaceutyczne do wstrzykiwania zawierające środek nierozpuszczalny w wodzie, środek przeciwpsychotyczny, laurynian sorbitanu i polisorbat 20
JO3410B1 (ar) *	2011-06-07	2019-10-20	Otsuka Pharma Co Ltd	تركيبة أريبيبرازول مجفف بالتبريد
JP6034377B2 (ja) *	2011-06-27	2016-11-30	シャンハイチョンシファーマシューティカルコーポレイション	アリピプラゾール医薬製剤及びその調製方法
CN102846616B (zh) *	2011-06-27	2015-05-06	上海中西制药有限公司	一种阿立哌唑制剂及其制备方法
TWI679977B (zh) *	2011-10-19	2019-12-21	大塚製藥股份有限公司	口服溶液
AU2013235519C1 (en)	2012-03-19	2018-04-26	Alkermes Pharma Ireland Limited	Pharmaaceutical compositions comprising fatty acid esters
US9993556B2 (en)	2012-03-19	2018-06-12	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising fatty glycerol esters
CA2867137C (en)	2012-03-19	2020-12-08	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol
JOP20200109A1 (ar)	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن
WO2014002553A1 (ja)	2012-06-29	2014-01-03	丸石製薬株式会社	アリピプラゾールの経口医薬製剤
JP5341282B1 (ja) *	2012-06-29	2013-11-13	丸石製薬株式会社	アリピプラゾールの経口医薬製剤
KR101571670B1 (ko) *	2012-08-08	2015-11-25	주식회사 씨엠지제약	아리피프라졸을 포함하는 경구용 속용 필름 제제
NZ730571A (en)	2012-09-19	2018-12-21	Alkermes Pharma Ireland Ltd	Pharmaceutical compositions having improved storage stability
MX358097B (es) *	2012-09-26	2018-08-06	Pfizer	Formulaciones liquidas de apixaban.
US8568747B1 (en)	2012-10-05	2013-10-29	Silvergate Pharmaceuticals, Inc.	Enalapril compositions
WO2014059363A1 (en) *	2012-10-11	2014-04-17	Antrim Pharmaceuticals Llc	Oral solution formulations of aripiprazole
PL2908859T3 (pl) *	2012-10-16	2017-10-31	Arven Ilac Sanayi Ve Ticaret As	Formulacje arypiprazolu
US10154988B2 (en)	2012-11-14	2018-12-18	The Johns Hopkins University	Methods and compositions for treating schizophrenia
JP6203682B2 (ja) *	2013-07-10	2017-09-27	共和薬品工業株式会社	アリピプラゾール含有水性液剤
CN103393594A (zh) *	2013-08-22	2013-11-20	万特制药(海南)有限公司	一种新的阿立哌唑的制剂组合物
BR112016021535A8 (pt)	2014-03-20	2021-07-20	Alkermes Pharma Ireland Ltd	kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
WO2016189504A1 (en) *	2015-05-28	2016-12-01	Leiutis Pharmaceuticals Pvt Ltd	Non-lyophilized compositions of aripiprazole and methods of preparation thereof
JP6039849B1 (ja) *	2015-06-12	2016-12-07	高田製薬株式会社	アリピプラゾール含有内用液剤
WO2017025930A1 (en)	2015-08-12	2017-02-16	Ftf Pharma Private Limited	Oral solution of aripiprazole
US9463183B1 (en)	2015-10-30	2016-10-11	Silvergate Pharmaceuticals, Inc.	Lisinopril formulations
US9669008B1 (en)	2016-03-18	2017-06-06	Silvergate Pharmaceuticals, Inc.	Enalapril formulations
CN108434146A (zh) *	2017-02-16	2018-08-24	天津国际生物医药联合研究院	一种hiv-1整合酶抑制剂的溶液剂及其制备方法和应用
CN109498556A (zh) *	2017-09-15	2019-03-22	万特制药(海南)有限公司	阿立哌唑口服溶液及其制备方法
AU2019230014B2 (en)	2018-03-05	2024-11-28	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy
CN112666267B (zh) *	2019-10-15	2023-09-26	上海上药中西制药有限公司	一种阿立哌唑药品有关物质的检测方法
JP2023173950A (ja) *	2022-05-27	2023-12-07	同仁医薬化工株式会社	経口液剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU843739A3 (ru)	1978-02-17	1981-06-30	Карл Томэ Гмбх (Фирма)	Способ получени карбостириловыхили ОКСиНдОлОВыХ пРОизВОдНыХ
JPS54130587A (en) *	1978-03-30	1979-10-09	Otsuka Pharmaceut Co Ltd	Carbostyryl derivative
PH17194A (en) *	1980-03-06	1984-06-19	Otsuka Pharma Co Ltd	Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS5959663A (ja)	1982-09-29	1984-04-05	Otsuka Pharmaceut Co Ltd	カルボスチリル誘導体−シクロデキストリン包接化合物
US5006528A (en) *	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
DE3933027A1 (de) *	1989-09-29	1991-04-11	Schering Ag	Kombinationspraeparat mit antithrombotischer wirkung
JP3265680B2 (ja) *	1992-03-12	2002-03-11	大正製薬株式会社	経口製剤用組成物
US5457099A (en)	1992-07-02	1995-10-10	Sawai Pharmaceutical Co., Ltd.	Carbostyril derivatives and antiallergic agent
TW254855B (no) *	1993-07-28	1995-08-21	Otsuka Pharma Co Ltd
JP2001518879A (ja) *	1997-03-31	2001-10-16	ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド	薬剤化合物の向上した浸透性のための溶媒システム
US20030077227A1 (en) *	1997-10-01	2003-04-24	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO2000013506A2 (en) *	1998-09-03	2000-03-16	Alcide Corporation	Freeze-resistant topical germicides and methods related thereto
US20020076437A1 (en) *	2000-04-12	2002-06-20	Sanjeev Kothari	Flashmelt oral dosage formulation
CA2311734C (en) *	2000-04-12	2011-03-08	Bristol-Myers Squibb Company	Flash-melt oral dosage formulation

2002
- 2002-03-28 MY MYPI20021124A patent/MY129350A/en unknown
- 2002-04-15 AR ARP020101366A patent/AR033168A1/es unknown
- 2002-04-19 TW TW091108139A patent/TWI337865B/zh not_active IP Right Cessation
- 2002-04-24 EP EP11190103.9A patent/EP2436384B2/en not_active Expired - Lifetime
- 2002-04-24 AU AU2002254722A patent/AU2002254722B2/en not_active Expired
- 2002-04-24 ES ES02723964T patent/ES2377855T3/es not_active Expired - Lifetime
- 2002-04-24 IL IL15820202A patent/IL158202A0/xx active IP Right Grant
- 2002-04-24 BR BR0208986-6A patent/BR0208986A/pt active Search and Examination
- 2002-04-24 RS YU84703A patent/RS52082B/sr unknown
- 2002-04-24 HR HR20030870A patent/HRP20030870B1/xx not_active IP Right Cessation
- 2002-04-24 KR KR1020037013943A patent/KR100909329B1/ko not_active Expired - Lifetime
- 2002-04-24 SK SK1264-2003A patent/SK287948B6/sk not_active IP Right Cessation
- 2002-04-24 CA CA002445276A patent/CA2445276C/en not_active Expired - Fee Related
- 2002-04-24 AT AT02723964T patent/ATE537831T1/de active
- 2002-04-24 RU RU2003132426/15A patent/RU2295960C2/ru not_active IP Right Cessation
- 2002-04-24 GE GE5332A patent/GEP20053602B/en unknown
- 2002-04-24 PL PL364666A patent/PL206882B1/pl unknown
- 2002-04-24 JP JP2002582939A patent/JP4401077B2/ja not_active Expired - Lifetime
- 2002-04-24 UA UA20031110599A patent/UA76144C2/uk unknown
- 2002-04-24 EE EEP200300523A patent/EE05581B1/xx not_active IP Right Cessation
- 2002-04-24 CZ CZ2003-2821A patent/CZ306181B6/cs not_active IP Right Cessation
- 2002-04-24 DK DK02723964.9T patent/DK1381367T3/da active
- 2002-04-24 EP EP02723964A patent/EP1381367B1/en not_active Expired - Lifetime
- 2002-04-24 UY UY27273A patent/UY27273A1/es not_active Application Discontinuation
- 2002-04-24 HU HU0303946A patent/HU230456B1/hu not_active IP Right Cessation
- 2002-04-24 PT PT02723964T patent/PT1381367E/pt unknown
- 2002-04-24 MX MXPA03009728A patent/MXPA03009728A/es active IP Right Grant
- 2002-04-24 CN CN028112148A patent/CN1512884B/zh not_active Ceased
- 2002-04-24 US US10/131,304 patent/US6977257B2/en not_active Expired - Lifetime
- 2002-04-24 WO PCT/US2002/013048 patent/WO2002085366A1/en not_active Ceased
- 2002-04-24 NZ NZ528550A patent/NZ528550A/en not_active IP Right Cessation
- 2002-04-25 PE PE2002000346A patent/PE20021086A1/es not_active Application Discontinuation
2003
- 2003-10-01 IL IL158202A patent/IL158202A/en not_active IP Right Cessation
- 2003-10-01 BG BG108216A patent/BG66177B1/bg unknown
- 2003-10-06 ZA ZA200307797A patent/ZA200307797B/en unknown
- 2003-10-14 IS IS6994A patent/IS2863B/is unknown
- 2003-10-21 NO NO20034705A patent/NO324606B1/no not_active IP Right Cessation
2012
- 2012-03-14 CY CY20121100273T patent/CY1112606T1/el unknown

Also Published As

Publication number	Publication date
BR0208986A (pt)	2004-04-20
HRP20030870A2 (en)	2004-06-30
JP4401077B2 (ja)	2010-01-20
MXPA03009728A (es)	2004-01-29
EP2436384B2 (en)	2018-05-23
US20020193438A1 (en)	2002-12-19
EP1381367A4 (en)	2009-07-01
HUP0303946A2 (hu)	2004-04-28
ES2377855T3 (es)	2012-04-02
UA76144C2 (uk)	2006-07-17
EE05581B1 (et)	2012-10-15
US6977257B2 (en)	2005-12-20
SK287948B6 (sk)	2012-06-04
KR100909329B1 (ko)	2009-07-24
ZA200307797B (en)	2004-10-06
SK12642003A3 (sk)	2004-07-07
NO324606B1 (no)	2007-11-26
EE200300523A (et)	2004-02-16
HK1058316A1 (en)	2004-05-14
CY1112606T1 (el)	2016-02-10
RU2003132426A (ru)	2005-04-20
BG66177B1 (bg)	2011-11-30
HK1168792A1 (en)	2013-01-11
EP2436384B1 (en)	2015-06-10
EP2436384A2 (en)	2012-04-04
RU2295960C2 (ru)	2007-03-27
CZ20032821A3 (cs)	2004-09-15
DK1381367T3 (da)	2012-04-10
EP1381367A1 (en)	2004-01-21
NO20034705D0 (no)	2003-10-21
WO2002085366A1 (en)	2002-10-31
MY129350A (en)	2007-03-30
CA2445276C (en)	2009-10-13
AR033168A1 (es)	2003-12-03
ATE537831T1 (de)	2012-01-15
AU2002254722B2 (en)	2006-11-09
CA2445276A1 (en)	2002-10-31
IL158202A0 (en)	2004-05-12
GEP20053602B (en)	2005-08-10
IL158202A (en)	2008-04-13
IS6994A (is)	2003-10-14
PE20021086A1 (es)	2002-12-14
TWI337865B (en)	2011-03-01
PT1381367E (pt)	2012-03-01
PL364666A1 (en)	2004-12-13
PL206882B1 (pl)	2010-10-29
KR20030096332A (ko)	2003-12-24
HRP20030870B1 (en)	2011-10-31
EP2436384A3 (en)	2012-09-19
BG108216A (bg)	2004-12-30
IS2863B (is)	2013-12-15
HU230456B1 (hu)	2016-07-28
UY27273A1 (es)	2002-11-29
JP2004532225A (ja)	2004-10-21
CN1512884B (zh)	2010-05-26
YU84703A (sh)	2006-08-17
CZ306181B6 (cs)	2016-09-14
RS52082B (sr)	2012-06-30
EP1381367B1 (en)	2011-12-21
NZ528550A (en)	2005-03-24
CN1512884A (zh)	2004-07-14
HUP0303946A3 (en)	2005-06-28

Publication	Publication Date	Title
NO20034705D0 (no)	2003-10-21	Aripiprazol oral lösning
NO20042121D0 (no)	2004-05-24	Kinolinforbindelse
NL300912I2 (nl)	2018-09-27	nonacog beta pegol
NO2014027I2 (no)	2014-10-27	aripiprazol
EP1451156A4 (en)	2005-05-25	4-AMINOCHINOLINVERBINDUNGEN
DK1406628T3 (da)	2006-07-03	Tetrahydroquinolin-derivater
IS7016A (is)	2003-11-05	Ný 4-anilínókínólín-3-karboxamíð
NO20014597D0 (no)	2001-09-21	Fremgangsmåte
DE60311233D1 (de)	2007-03-08	Chinolinderivate
DE10107471B4 (de)	2005-04-28	Vitrine
ATA2892002A (de)	2005-08-15	Beschlag
ATE405973T1 (de)	2008-09-15	Steckverbindung
DE10295574D2 (de)	2004-10-28	Geräusch-gesteuertes Beatmungsgerät
UA6063S (uk)	2002-06-17	Вкладиш
NO20015559D0 (no)	2001-11-14	Kreklinggel±
FI20020353A7 (fi)	2003-04-13	Niittomurskain
SE0102054D0 (sv)	2001-06-08	New Combination
SE0102059D0 (sv)	2001-06-08	New combination
NO20015321D0 (no)	2001-10-30	Ventilasjonsanlegg
ITPG20010050A0 (it)	2001-10-10	Cosmeticus universal
SE0102987D0 (sv)	2001-09-09	Länsa
NO20052727D0 (no)	2005-06-07	Tetrahydrokinolinderivater
SE0100798D0 (sv)	2001-03-08	New use
SE0103767D0 (sv)	2001-11-09	New use
SE0103768D0 (sv)	2001-11-09	New use

Legal Events

Date	Code	Title	Description
2016-04-25	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: OTSUKA PHARMACEUTICAL CO., US
2019-11-25	MM1K	Lapsed by not paying the annual fees